Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Novocure (NVCR) announced that Optune Lua has received a CE Mark for the treatment of adult patients with metastatic non-small cell lung cancer ...

BAAR, Switzerland - Novocure (NASDAQ: NVCR), a medical technology company with a market capitalization of $1.7 billion, has announced the CE Mark approval of Optune Lua for the treatment of ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...

Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of ...